EUCTR2018-003278-28-FR进行中（未招募）1 期
A multicentre randomized, double-blind (sponsor open), placebo-controlled Phase 2 study to evaluate the safety, tolerability, efficacy, dose-response, pharmacokinetics and pharmacodynamics of repeat dosing of an anti-LAG3 cell depleting monoclonal antibody (GSK2831781) in patients with active ulcerative colitis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •AGE and WEIGHT: Participant must be 18 years of age or older and >40kg at the time of signing the informed consent.
- •TYPE OF PARTICIPANT AND DISEASE CHARACTERISTICS:
- •Participants who have a:
- •-Diagnosis of ulcerative colitis, established at least 3 months prior to screening, as documented by diagnostic sigmoidoscopy or colonoscopy, and biopsy.
- •-Complete Mayo Score of 6 to 12, with disease extending =15cm from the anal verge, with a centrally read endoscopic subscore of =2 at screening endoscopy, and a rectal bleeding subscore =1.
- •-A history of at least one of the following:
- •(1) Inadequate response to, loss of response to, or intolerance to azathioprine or mercaptopurine (including thiopurine methyltransferase (TPMT) genetic mutation precluding use), ciclosporin, tacrolimus or methotrexate.
- •(2) Inadequate response to, intolerance to, or demonstrated dependence on oral corticosteroids.
- •(3) Inadequate response to, loss of response to, or intolerance to one biologic class ONLY for the treatment of UC: either one or more anti-TNF therapies (e.g. infliximab, adalimumab, golimumab, or biosimilar) OR vedolizumab.
- •- Surveillance colonoscopy (performed according to local standards) within 12 months of screening (or during screening, if required) for participants with:
- •(1) Pancolitis of >8 years duration; or
- •(2) Patients with left-sided colitis of >12 years duration; or
- •(3) Patients with primary sclerosing cholangitis.
- •(4) For patients for whom this criterion does not apply, colorectal cancer surveillance should be undertaken according to local or national guidelines for patients with age =50, or with other known risk factors for colorectal cancer.
- •Female participants:
- •- A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
- •(1) Not a woman of childbearing potential (WOCBP),
- •(2) A WOCBP who agrees to use a highly effective contraceptive method for at least 4 weeks prior to dosing, until the Follow-Up visit.
- •INFORMED CONSENT
- •-Capable of giving signed informed consent as described in the protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 280
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •Medical Conditions:
- •(1) Current diagnosis of indeterminate colitis, inflammatory bowel disease-unclassified, Crohn's Disease, infectious colitis, or ischaemic colitis
- •(2) Fulminant UC (as defined by 6 bloody stools daily AND 1 or more of: i) body temperature =100.4°F (or 38°C) or ii) heart rate >90 beats per minute), or toxic megacolon
- •(3) Prior extensive colonic resection, subtotal or total colectomy, or proctocolectomy, or planned surgery for UC
- •(4) Any uncontrolled medical conditions, other than active UC, that in the opinion of the investigator put the participant at unacceptable risk or interfere with study assessments or integrity of the data. Other medical conditions should be stable at the time of screening and be expected to remain stable for the duration of the study
- •(5) Unstable lifestyle factors, such as alcohol use to excess or recreational drug use, to the extent that in the opinion of the investigator they would interfere with the ability of a participant to complete the study
- •(6) An active infection or a history of serious infections as described fully in the protocol.
- •(7) Current or history of chronic liver or biliary disease (with the exception of Gilbert’s syndrome, asymptomatic gallstones or uncomplicated fatty liver disease)
- •(8) Hereditary or acquired immunodeficiency disorder, including immunoglobulin deficiency (unless the participant has a documented history of selective IgA deficiency)
- •(9) A major organ transplant or haematopoietic stem cell/marrow transplant
- •(10) Any planned major surgical procedure during the study
- •(11) A history of malignant neoplasm within the last 5 years, except for adequately treated non-metastatic basal or squamous cell cancers of the skin (within 1 year) or carcinoma in situ of the uterine cervix (within 3 years) that has been fully treated and shows no evidence of recurrence
- •PRIOR/CONCOMITANT THERAPY:
- •(12) A change in dose of oral sulfasalazine or aminosalicylate within 2 weeks prior to baseline endoscopy
- •(13) Greater than 20mg/day oral prednisolone (or equivalent), or a change in dose of corticosteroid within 2 weeks prior to baseline endoscopy, or be unable to maintain a stable dose of corticosteroids (=20mg oral prednisolone or equivalent) until Week 12
- •(14) Topical (rectal) corticosteroids or topical (rectal) aminosalicylate within 2 weeks prior to baseline endoscopy
- •(15) Initiation or a change in dose of mercaptopurine or azathioprine (including initiation or discontinuation of allopurinol) or methotrexate within 8 weeks prior to baseline endoscopy
- •(16) Treatment with ciclosporin, tacrolimus or thalidomide within 4 weeks prior to baseline endoscopy
- •(17) Treatment with an anti-TNF biologic within 8 weeks prior to baseline endoscopy, or vedolizumab within 12 weeks prior to baseline endoscopy
- •(18) History of treatment with vedolizumab AND an anti-TNF biologic, regardless of treatment response (unless exposure to one or both drugs was only within a clinical trial setting)
- •(19) History of treatment with a monoclonal antibody therapy or targeted small molecule therapy for the treatment of UC not listed above
- •(20) Received live vaccination within 4 weeks of Day 1 or plan to receive during the study until Follow-Up
- •PRIOR/CONCURRENT CLINICAL STUDY EXPERIENCE:
- •(21) Participated in a clinical trial and received an IP within the following time period prior to the first dosing day in the current study: 3 months, 5 half-lives, or twice the duration of the biological effect of the IP (whichev
研究者
相似试验
进行中（未招募）
1 期
Safety, tolerability, efficacy and dose-response of GSK2831781 in ulcerative colitis.lcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2018-003278-28-HUGlaxoSmithKline Research & Development Limited320
进行中（未招募）
1 期
A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with active ulcerative colitisEUCTR2016-001833-29-NLGlaxoSmithKline Research & Development Ltd36
进行中（未招募）
1 期
A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with moderate to severe rheumatoid arthritis.EUCTR2016-000912-13-GBGlaxoSmithKline Research & Development Ltd52
进行中（未招募）
1 期
A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with active ulcerative colitisActive ulcerative colitisMedDRA version: 20.0Level: HLGTClassification code 10017969Term: Gastrointestinal inflammatory conditionsSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2016-001833-29-SEGlaxoSmithKline Research & Development Ltd36
已完成
2 期
A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with active ulcerative colitis (study 202152)10017969ulcerative colitisNL-OMON45582GlaxoSmithKline3